A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

Inclusion Criteria: * The participant has well-differentiated or moderately-differentiated, histologically confirmed neuroendocrine carcinoma, including carcinoid of any location and islet cell tumors * The participant has metastatic disease at the time of study entry * The participant must have a tumor measurable according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, measurable by elevated tumor markers (eg, 24-hour urine 5-HIAA, chromogranin A, adrenocorticotropin hormone (ACTH), gastrin, or other tumor specific biochemical markers), or both * The participant is age ≥ 18 years * The participant's tumor has Ki-67 expression ≤ 20% * The participant is receiving depot octreotide therapy at the time of enrolling into the study * The participant has received 0 - 2 systemic anticancer regimens in addition to depot octreotide, which may have included chemotherapy, interferon, antiangiogenic therapy, other targeted treatments, or a combination of such treatments * The participant is no longer a candidate for surgery, embolization, or radiofrequency ablation therapy * The participant has experienced radiographic, biochemical, and/or scintigraphic disease progression while on a regimen that includes octreotide * The participant has completed prior chemotherapy and/or radiotherapy with curative intent at least 3 weeks prior to the administration of the first dose of study therapy. Participants that have received palliative radiation therapy to bony metastases …